Trimethoprim-Sulfamethoxazole or Doxycycline for Skin and Soft Tissue Infections
Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
Background: In many communities, skin and soft tissue infections (SSTI) with MRSA have become
more prevalent than infections with β-lactam susceptible bacteria. This has necessitated
altered empiric antimicrobial therapy of SSTI to cover MRSA.
Objective: To evaluate empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for
outpatient SSTI in an area of high MRSA prevalence.
Design: Randomized, prospective, open-label investigation. Setting: Emergency Department of
Parkland Hospital in Dallas, Texas. Patients: Adults with SSTI. Intervention: Empiric oral
therapy with trimethoprim-sulfamethoxazole (160 mg/800 mg, twice daily) or doxycycline (100
mg, twice daily).
Measurement: The primary endpoint was clinical failure defined as hospitalization or change
in antibiotic therapy over the 10 to 14 days after initial emergency department evaluation.
Phase:
N/A
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Treatments:
Doxycycline Sulfamethoxazole Trimethoprim Trimethoprim, Sulfamethoxazole Drug Combination